FDA moves to block foreign sales of Cipro via Internet - NewsOn6.com - Tulsa, OK - News, Weather, Video and Sports - KOTV.com |

FDA moves to block foreign sales of Cipro via Internet

Updated:
WASHINGTON (AP) _ The Food and Drug Administration said Thursday it has issued warning letters to 11 foreign pharmacies to stop selling the antibiotic Cipro to Americans via the Internet.

The agency said it also is advising the U.S. Customs Service that shipments from these companies may be detained and refused entry into the United States.

Cipro was the drug first recommended to combat anthrax, which has struck in four East Coast communities, most likely through tainted mail.

Fear that the disease will spread has prompted worried people in many areas to seek prescriptions for the drug and others have crossed into Mexico to buy it.

FDA said it was unable to determine that the Cipro offered for sale by the 11 pharmacies was made in accordance with U.S. specification and, therefore, sale of the drug in the United States may be illegal.

Thursday's warning letters were sent to:

_ Farmacia Cerati, S. Damiano d'Asti, Italy.

_ Farmamondo, Chiasso, Switzerland.

_ JFW Enterprises, Hermosillo, Mexico.

_ Masters Marketing Company, Harrow, United Kingdom.

_ Mediplan Health Consulting Inc., Minnedosa, Manitoba, Canada.

_ Rhino Corporate Communications, Calgary, Alberta, Canada.

_ Pharma Group, Lisbon, Portugal.

_ Pharmacy International Inc., Kuala Lumpur, Malaysia.

_ Point Douglas Pharmacy, Winnipeg, Manitoba, Canada.

_ Hans-Georg Seiler, Krefeld, New Zealand.

_ USA Medicine.com Ltd., Dublin, Ireland.
Powered by Frankly
News On 6
303 N. Boston Ave.
Tulsa, OK 74103
Newson6.com is proud to provide Oklahomans with timely and relevant news and information, sharing the stories, pictures and loves of Oklahomans across our great state.
All content © Copyright 2000 - 2018 KOTV. Oklahoma Traveler™ is a registered trademark of Griffin Communications. All Rights Reserved.
For more information on this site, please read our Privacy Policy, and Terms of Service, and Ad Choices.